Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Identifieur interne : 001A10 ( PubMed/Curation ); précédent : 001A09; suivant : 001A11Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Auteurs : K. Lindemann [Oman] ; G. Kristensen [Norvège] ; M R Mirza [Danemark] ; L. Davies [Australie] ; F. Hilpert [Allemagne] ; I. Romero [Espagne] ; A. Ayhan [Turquie] ; A. Burges [Allemagne] ; M J Rubio [Espagne] ; F. Raspagliesi [Italie] ; M. Huizing [Belgique] ; G-J Creemers [Pays-Bas] ; M. Lykka [Grèce] ; C K Lee [Australie] ; V. Gebski [Australie] ; E. Pujade-Lauraine [France]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2016.
Abstract
Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone. We assessed concordance between CA-125-defined and RECIST-defined PD using data from the Gynecologic Cancer InterGroup (GCIG) randomized phase III AURELIA trial in platinum-resistant ovarian cancer (PROC).
DOI: 10.1093/annonc/mdw238
PubMed: 27407100
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A34
Links to Exploration step
pubmed:27407100Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.</title>
<author><name sortKey="Lindemann, K" sort="Lindemann, K" uniqKey="Lindemann K" first="K" last="Lindemann">K. Lindemann</name>
<affiliation wicri:level="1"><nlm:affiliation>NSGO and Department of Gynecological Cancer, The Norwegian Radium Hospital, Oslo University Hospital, Oslo stinalindemann@hotmail.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
<wicri:regionArea>NSGO and Department of Gynecological Cancer, The Norwegian Radium Hospital, Oslo University Hospital</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kristensen, G" sort="Kristensen, G" uniqKey="Kristensen G" first="G" last="Kristensen">G. Kristensen</name>
<affiliation wicri:level="1"><nlm:affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Oslo, Norway.</nlm:affiliation>
<country xml:lang="fr">Norvège</country>
<wicri:regionArea>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Oslo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mirza, M R" sort="Mirza, M R" uniqKey="Mirza M" first="M R" last="Mirza">M R Mirza</name>
<affiliation wicri:level="1"><nlm:affiliation>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Davies, L" sort="Davies, L" uniqKey="Davies L" first="L" last="Davies">L. Davies</name>
<affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hilpert, F" sort="Hilpert, F" uniqKey="Hilpert F" first="F" last="Hilpert">F. Hilpert</name>
<affiliation wicri:level="1"><nlm:affiliation>AGO and Oncological Center, Hospital Jerusalem, Hamburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>AGO and Oncological Center, Hospital Jerusalem, Hamburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Romero, I" sort="Romero, I" uniqKey="Romero I" first="I" last="Romero">I. Romero</name>
<affiliation wicri:level="1"><nlm:affiliation>GEICO and Valencia Institute of Oncology, Valencia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>GEICO and Valencia Institute of Oncology, Valencia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ayhan, A" sort="Ayhan, A" uniqKey="Ayhan A" first="A" last="Ayhan">A. Ayhan</name>
<affiliation wicri:level="1"><nlm:affiliation>GINECO and Baskent University, Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>GINECO and Baskent University, Ankara</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Burges, A" sort="Burges, A" uniqKey="Burges A" first="A" last="Burges">A. Burges</name>
<affiliation wicri:level="1"><nlm:affiliation>AGO and Department of Gynecology and Obstetrics, Hospital of University of Munich, Campus Großhadern, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>AGO and Department of Gynecology and Obstetrics, Hospital of University of Munich, Campus Großhadern, Munich</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rubio, M J" sort="Rubio, M J" uniqKey="Rubio M" first="M J" last="Rubio">M J Rubio</name>
<affiliation wicri:level="1"><nlm:affiliation>GEICO and University Hospital Queen Sofía, Córdoba, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>GEICO and University Hospital Queen Sofía, Córdoba</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Raspagliesi, F" sort="Raspagliesi, F" uniqKey="Raspagliesi F" first="F" last="Raspagliesi">F. Raspagliesi</name>
<affiliation wicri:level="1"><nlm:affiliation>MITO and National Tumour Institute of Milan, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>MITO and National Tumour Institute of Milan, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Huizing, M" sort="Huizing, M" uniqKey="Huizing M" first="M" last="Huizing">M. Huizing</name>
<affiliation wicri:level="1"><nlm:affiliation>BGOG and Antwerp University Hospital, Edegem, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>BGOG and Antwerp University Hospital, Edegem</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Creemers, G J" sort="Creemers, G J" uniqKey="Creemers G" first="G-J" last="Creemers">G-J Creemers</name>
<affiliation wicri:level="1"><nlm:affiliation>DGOG and Catharina Hospital, Eindhoven, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>DGOG and Catharina Hospital, Eindhoven</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lykka, M" sort="Lykka, M" uniqKey="Lykka M" first="M" last="Lykka">M. Lykka</name>
<affiliation wicri:level="1"><nlm:affiliation>HECOG and University of Athens, Athens, Greece.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>HECOG and University of Athens, Athens</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, C K" sort="Lee, C K" uniqKey="Lee C" first="C K" last="Lee">C K Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gebski, V" sort="Gebski, V" uniqKey="Gebski V" first="V" last="Gebski">V. Gebski</name>
<affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name>
<affiliation wicri:level="1"><nlm:affiliation>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27407100</idno>
<idno type="pmid">27407100</idno>
<idno type="doi">10.1093/annonc/mdw238</idno>
<idno type="wicri:Area/PubMed/Corpus">001A34</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A34</idno>
<idno type="wicri:Area/PubMed/Curation">001A10</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A10</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.</title>
<author><name sortKey="Lindemann, K" sort="Lindemann, K" uniqKey="Lindemann K" first="K" last="Lindemann">K. Lindemann</name>
<affiliation wicri:level="1"><nlm:affiliation>NSGO and Department of Gynecological Cancer, The Norwegian Radium Hospital, Oslo University Hospital, Oslo stinalindemann@hotmail.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
<wicri:regionArea>NSGO and Department of Gynecological Cancer, The Norwegian Radium Hospital, Oslo University Hospital</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kristensen, G" sort="Kristensen, G" uniqKey="Kristensen G" first="G" last="Kristensen">G. Kristensen</name>
<affiliation wicri:level="1"><nlm:affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Oslo, Norway.</nlm:affiliation>
<country xml:lang="fr">Norvège</country>
<wicri:regionArea>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Oslo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mirza, M R" sort="Mirza, M R" uniqKey="Mirza M" first="M R" last="Mirza">M R Mirza</name>
<affiliation wicri:level="1"><nlm:affiliation>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Davies, L" sort="Davies, L" uniqKey="Davies L" first="L" last="Davies">L. Davies</name>
<affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hilpert, F" sort="Hilpert, F" uniqKey="Hilpert F" first="F" last="Hilpert">F. Hilpert</name>
<affiliation wicri:level="1"><nlm:affiliation>AGO and Oncological Center, Hospital Jerusalem, Hamburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>AGO and Oncological Center, Hospital Jerusalem, Hamburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Romero, I" sort="Romero, I" uniqKey="Romero I" first="I" last="Romero">I. Romero</name>
<affiliation wicri:level="1"><nlm:affiliation>GEICO and Valencia Institute of Oncology, Valencia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>GEICO and Valencia Institute of Oncology, Valencia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ayhan, A" sort="Ayhan, A" uniqKey="Ayhan A" first="A" last="Ayhan">A. Ayhan</name>
<affiliation wicri:level="1"><nlm:affiliation>GINECO and Baskent University, Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>GINECO and Baskent University, Ankara</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Burges, A" sort="Burges, A" uniqKey="Burges A" first="A" last="Burges">A. Burges</name>
<affiliation wicri:level="1"><nlm:affiliation>AGO and Department of Gynecology and Obstetrics, Hospital of University of Munich, Campus Großhadern, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>AGO and Department of Gynecology and Obstetrics, Hospital of University of Munich, Campus Großhadern, Munich</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rubio, M J" sort="Rubio, M J" uniqKey="Rubio M" first="M J" last="Rubio">M J Rubio</name>
<affiliation wicri:level="1"><nlm:affiliation>GEICO and University Hospital Queen Sofía, Córdoba, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>GEICO and University Hospital Queen Sofía, Córdoba</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Raspagliesi, F" sort="Raspagliesi, F" uniqKey="Raspagliesi F" first="F" last="Raspagliesi">F. Raspagliesi</name>
<affiliation wicri:level="1"><nlm:affiliation>MITO and National Tumour Institute of Milan, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>MITO and National Tumour Institute of Milan, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Huizing, M" sort="Huizing, M" uniqKey="Huizing M" first="M" last="Huizing">M. Huizing</name>
<affiliation wicri:level="1"><nlm:affiliation>BGOG and Antwerp University Hospital, Edegem, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>BGOG and Antwerp University Hospital, Edegem</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Creemers, G J" sort="Creemers, G J" uniqKey="Creemers G" first="G-J" last="Creemers">G-J Creemers</name>
<affiliation wicri:level="1"><nlm:affiliation>DGOG and Catharina Hospital, Eindhoven, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>DGOG and Catharina Hospital, Eindhoven</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lykka, M" sort="Lykka, M" uniqKey="Lykka M" first="M" last="Lykka">M. Lykka</name>
<affiliation wicri:level="1"><nlm:affiliation>HECOG and University of Athens, Athens, Greece.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>HECOG and University of Athens, Athens</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, C K" sort="Lee, C K" uniqKey="Lee C" first="C K" last="Lee">C K Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gebski, V" sort="Gebski, V" uniqKey="Gebski V" first="V" last="Gebski">V. Gebski</name>
<affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name>
<affiliation wicri:level="1"><nlm:affiliation>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title>
<idno type="eISSN">1569-8041</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone. We assessed concordance between CA-125-defined and RECIST-defined PD using data from the Gynecologic Cancer InterGroup (GCIG) randomized phase III AURELIA trial in platinum-resistant ovarian cancer (PROC).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27407100</PMID>
<DateCreated><Year>2016</Year>
<Month>07</Month>
<Day>26</Day>
</DateCreated>
<DateRevised><Year>2016</Year>
<Month>10</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>27</Volume>
<Issue>8</Issue>
<PubDate><Year>2016</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
<ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.</ArticleTitle>
<Pagination><MedlinePgn>1505-10</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdw238</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone. We assessed concordance between CA-125-defined and RECIST-defined PD using data from the Gynecologic Cancer InterGroup (GCIG) randomized phase III AURELIA trial in platinum-resistant ovarian cancer (PROC).</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients with PROC were randomized to receive single-agent chemotherapy with or without bevacizumab. PD by CA-125 was defined according to GCIG criteria (except that confirmatory CA-125 measurement was not required). This exploratory analysis included patients with RECIST PD and a CA-125 reading ≤28 days before and ≤21 days after RECIST-defined PD.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 218 eligible patients, only 94 (43%, 95% confidence interval 36% to 50%) had concordant RECIST and CA-125 PD status (42% in the chemotherapy-alone arm; 45% in the bevacizumab combination arm, P = 0.6). There was no evidence of CA-125-defined PD in the remaining 124 patients despite PD according to imaging. There were no significant differences in baseline characteristics between patients with PD defined by both RECIST and CA-125 and those with RECIST-only PD. CA-125 was even less sensitive in detecting PD in patients with early (<8 weeks after randomization) compared with later RECIST-defined PD (69% versus 53%, respectively, not meeting CA-125 criteria; P = 0.053). There was no significant difference in survival after PD in patients with concordant PD by RECIST and CA-125 versus those with PD only by RECIST. We validated our findings in an independent study population of PROC.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this platinum-resistant population, PD was typically detected earlier by imaging than by CA-125, irrespective of bevacizumab treatment. Disease status by CA-125 at the time of PD was not prognostic for overall survival. Regular radiologic assessment as well as symptom benefit assessment should be considered during PROC follow-up.</AbstractText>
<CopyrightInformation>© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lindemann</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>NSGO and Department of Gynecological Cancer, The Norwegian Radium Hospital, Oslo University Hospital, Oslo stinalindemann@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kristensen</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Oslo, Norway.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mirza</LastName>
<ForeName>M R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo><Affiliation>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Davies</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hilpert</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>AGO and Oncological Center, Hospital Jerusalem, Hamburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Romero</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>GEICO and Valencia Institute of Oncology, Valencia, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ayhan</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>GINECO and Baskent University, Ankara, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Burges</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>AGO and Department of Gynecology and Obstetrics, Hospital of University of Munich, Campus Großhadern, Munich, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rubio</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>GEICO and University Hospital Queen Sofía, Córdoba, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Raspagliesi</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>MITO and National Tumour Institute of Milan, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Huizing</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>BGOG and Antwerp University Hospital, Edegem, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Creemers</LastName>
<ForeName>G-J</ForeName>
<Initials>GJ</Initials>
<AffiliationInfo><Affiliation>DGOG and Catharina Hospital, Eindhoven, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lykka</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>HECOG and University of Athens, Athens, Greece.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>C K</ForeName>
<Initials>CK</Initials>
<AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gebski</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pujade-Lauraine</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>07</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Ann Oncol</MedlineTA>
<NlmUniqueID>9007735</NlmUniqueID>
<ISSNLinking>0923-7534</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CA-125</Keyword>
<Keyword MajorTopicYN="N">RECIST</Keyword>
<Keyword MajorTopicYN="N">ovarian cancer</Keyword>
<Keyword MajorTopicYN="N">platinum resistance</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>03</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>05</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>7</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>7</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>7</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27407100</ArticleId>
<ArticleId IdType="pii">mdw238</ArticleId>
<ArticleId IdType="doi">10.1093/annonc/mdw238</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A10 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001A10 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:27407100 |texte= Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27407100" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |